featured
Linvoseltamab for Relapsed/Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
J. Clin. Oncol 2024 Jun 16;[EPub Ahead of Print], N Bumma, J Richter, S Jagannath, HC Lee, JE Hoffman, A Suvannasankha, JA Zonder, MR Shah, S Lentzsch, R Baz, JJ Maly, S Namburi, MJ Pianko, JC Ye, KL Wu, R Silbermann, CK Min, MC Vekemans, M Munder, JM Byun, J Martínez-Lopez, K Cassady, M DeVeaux, D Chokshi, A Boyapati, A Hazra, GD Yancopoulos, LA Sirulnik, K Rodriguez Lorenc, GS Kroog, Y Houvras, MV DhodapkarFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.